Abstract 80MO
Background
CONSORT 2010 recommends the use of flow diagrams within Randomised Control Trials (RCTs). Phase I trial designs have dose-finding features not captured by flow diagrams for RCTs, yet there are currently no recommendations on diagrams for these trials. This project aims to: (1) assess the completeness of information in flow diagrams of phase I published trials based on CONSORT recommendations, and if additional features on dose (de-)escalation were presented; (2) propose new flow diagrams presenting how doses were (de-)escalated throughout the trial.
Methods
Flow diagrams were extracted from a random sample of 259 phase I papers across all diseases, published from 2011-2020 indexed in PubMed. Diagrams were scored out of 15 following CONSORT recommendations with an additional score for presence of (de-)escalation. New templates were proposed for features that were deficient and presented to 39 attendees at the 7th Early Phase Adaptive Workshop held in October 2022 and 11 members of the Drug Development Unit (DDU) team at the Institute of Cancer Research in December 2022.
Results
98 (38%) papers included a flow diagram. Flow diagrams best reported the number of patients allocated to intervention (95%) and received allocated intervention (55%). Flow diagrams were most deficient in the reporting of reasons for lost to follow up (2%) and reasons for not receiving allocated intervention (14%). Few (39%) presented dose-decision stages. Non-cancer trials presented more flow diagrams in their publications than cancer trials (56%, 20.9% respectively), with better quality of reporting (46.9%, 34.3%). Of the voting workshop attendees, 33/38 (87%) agreed or strongly agreed that for patients recruited in cohorts, presenting the (de-)escalation steps in the flow diagram is a useful feature, also expressed by the DDU team. Most workshop attendees (35/39, 90%) preferred a larger dose to be displayed higher up within the flow diagram than a smaller dose.
Conclusions
Most published trials do not provide a flow diagram, and for those that do, essential information is often omitted. Phase I flow diagrams capturing information on participant flow in the trial’s journey, encapsulated within one figure, are highly recommended to promote transparency and interpretability of trial results.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
70MO - Genomic profiling to expand precision cancer medicine in the real world: The ROME trial
Presenter: Andrea Botticelli
Session: Mini Oral session: Optimal tools and methods for developing and implementing precision therapeutics
Resources:
Abstract
Slides
Webcast
28MO - Adapting the Time-to-Event Continual Reassessment Method (TiTE-CRM) to include consolidation immunotherapy in a phase I drug-radiotherapy platform trial
Presenter: Jessica Kendall
Session: Mini Oral session: Optimal tools and methods for developing and implementing precision therapeutics
Resources:
Abstract
Slides
Webcast
79MO - Developing international consensus-driven SPIRIT and CONSORT extensions for early phase dose-finding clinical trials: The DEFINE (DosE FIndiNg Extensions) study
Presenter: Olga Solovyeva
Session: Mini Oral session: Optimal tools and methods for developing and implementing precision therapeutics
Resources:
Abstract
Slides
Webcast
Invited Discussant
Presenter: Jordi Rodon
Session: Mini Oral session: Optimal tools and methods for developing and implementing precision therapeutics
Resources:
Slides
Webcast
Oncology phase I trial design and conduct: Time for a change - MDICT Guidelines 2022
Presenter: Lesley Seymour
Session: Mini Oral session: Optimal tools and methods for developing and implementing precision therapeutics
Resources:
Slides
Webcast
Panel discussion
Presenter: Christina Yap
Session: Mini Oral session: Optimal tools and methods for developing and implementing precision therapeutics
Resources:
Webcast